Clinical Trials Sponsored by GeneTX Biotherapeutics, LLC

Total 53 results

Dermelix Biotherapeutics, LLC.

Withdrawn

A Cross-Sectional Natural History Study to Evaluate Sweat Volume and Other Phenotypic and Genetic Characteristics in Patients Affected by XLHED

XLHED

United States
Atara Biotherapeutics
Merck Sharp & Dohme LLC

Terminated

Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)

Nasopharyngeal Carcinoma | Nasopharyngeal Neoplasms | Epstein-Barr Virus Infections | Epstein-Barr Viraemia | Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)

United States
Bridge Biotherapeutics, Inc.
KCRN Research, LLC

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBT-877 in Healthy Subjects

Idiopathic Pulmonary Fibrosis

United States
Bridge Biotherapeutics, Inc.
KCRN Research, LLC

Completed

First-In-Human Study of BBT-401-1S Following Single and Multiple Ascending Doses in Healthy Volunteers

Ulcerative Colitis

United States
Bridge Biotherapeutics, Inc.
KCRN Research, LLC

Terminated

Efficacy and Safety of BBT-401-1S in Ulcerative Colitis

Ulcerative Colitis

United States
Aeglea Biotherapeutics
Merck Sharp & Dohme LLC

Completed

Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer

Small-cell Lung Cancer

United States, Puerto Rico
Bridge Biotherapeutics, Inc.
KCRN Research, LLC

Completed

Evaluate Safety, Pharmacokinetics and Pharmacodynamics of BBT-877 in Healthy Japanese Male

Healthy Participants

United States
Bridge Biotherapeutics, Inc.
KCRN Research, LLC

Completed

Assess the Drug Interactions of BBT-877 and Midazolam, Itraconazole, and Esomeprazole in Healthy Adult Subjects

Healthy Participants

United States
Immorna Biotherapeutics, Inc.
ICON plc

Recruiting

A Phase 1/2 Study to Assess the Safety and Immunogenicity of JCXH-221, an mRNA-based Broadly Protective COVID-19 Vaccine

COVID-19 | Infectious Disease

United States
Immorna Biotherapeutics, Inc.
ICON plc

Active, not recruiting

A First-in-Human Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine (JCXH-105)

Infectious Disease | Shingles | Herpes Zoster (HZ)

United States
TORL Biotherapeutics, LLC
Translational Research in Oncology

Recruiting

A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer

Hepatocellular Carcinoma | Advanced Solid Tumor

United States
Asher Biotherapeutics, Inc.
Merck Sharp & Dohme LLC

Recruiting

A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors

Melanoma | Renal Cell Carcinoma | Solid Tumor | Non Small Cell Lung Cancer | Squamous Cell Carcinoma of Head and Neck

United States
TORL Biotherapeutics, LLC
Translational Research in Oncology

Recruiting

First in Human Study of TORL-3-600 in Participants With Advanced Cancer

Colorectal Cancer | Advanced Solid Tumor

United States, Canada
TORL Biotherapeutics, LLC
Translational Research in Oncology

Recruiting

First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer

Gastric Cancer | Advanced Solid Tumor | Pancreas Cancer | Gastroesophageal Junction Adenocarcinoma

Korea, Republic of, United States
TORL Biotherapeutics, LLC
Translational Research in Oncology

Recruiting

First in Human Study of TORL-1-23 in Participants With Advanced Cancer (TRIO049)

Ovarian Cancer | NSCLC | Advanced Solid Tumor | Endometrial Cancer

United States
TILT Biotherapeutics Ltd.
Merck Sharp & Dohme LLC

Recruiting

Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small Cell Lung Cancer

Lung Cancer

United States
1ST Biotherapeutics, Inc.
Merck Sharp & Dohme LLC

Recruiting

A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849

Advanced Solid Tumor

United States
TILT Biotherapeutics Ltd.
Merck Sharp & Dohme LLC

Recruiting

Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Ovarian Cancer (PROTA)

Platinum-resistant Ovarian Cancer | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Refractory Fallopian Tube Carcinoma | Platinum-Refractory Primary Peritoneal Carcinoma | Platinum-refractory Ovarian Carcinoma | Platinum-Sensitive Ovarian... and other conditions

United States, Finland
TORL Biotherapeutics, LLC
Translational Research in Oncology

Recruiting

First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer

Gastric Cancer | Advanced Solid Tumor | Pancreas Cancer | Gastroesophageal Junction Adenocarcinoma

Korea, Republic of, United States
Ridgeback Biotherapeutics, LP
Merck Sharp & Dohme LLC

Completed

The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID)

SARS-CoV 2

United States
Ridgeback Biotherapeutics, LP
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19

SARS-CoV-2 Infection, COVID-19

United States
Esoterix Genetic Laboratories, LLC

Unknown

Validation of Saliva in the Esoterix Genetic Laboratories Fragile X Assay

Fragile X Syndrome

United States
Esoterix Genetic Laboratories, LLC

Unknown

Preterm Delivery Risk Prediction by Measurement of Prenatal Serum Screening Markers

Preterm Delivery

United States
Gene Surgery LLC

Recruiting

Safety, Tolerability and Pharmacokinetics Investigation of Stimotimagene Copolymerplasmid

Melanoma | Sarcoma | Uterine Cervical Neoplasms | Breast Neoplasms | Squamous Cell Carcinoma of Head and Neck | Vulvar Neoplasms | Anus Neoplasms | Penile Neoplasms

Russian Federation
Istituto Oncologico Veneto IRCCS
Janssen Diagnostics, LLC

Unknown

Circulating Melanoma Cells in Metastatic Patients Treated With Selective BRAF Inhibitors (CMCBRAF)

Metastatic Melanoma

Italy
Genetic Disease Investigators
Optos, PLC

Completed

Vascular Fundus Changes in Patients With High Probability of Chronic Cerebrospinal Venous Insufficiency (CCSVI)

Multiple Sclerosis | Ehlers-Danlos Syndrome

United States
AstraZeneca
Merck Sharp & Dohme LLC; Myriad Genetic Laboratories, Inc.

Completed

Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer (CONCERTO)

Recurrent Platinum Resistant Ovarian Cancer

United States
AstraZeneca
Merck Sharp & Dohme LLC; Myriad Genetic Laboratories, Inc.

Active, not recruiting

Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. (OlympiAD)

Breast Cancer Metastatic | BRCA 1 Gene Mutation | BRCA 2 Gene Mutation

Italy, Spain, United States, Czechia, Romania, France, Korea, Republic of, United Kingdom, Hungary, Japan, Peru, Poland, Russian Federation, Turkey, China, Taiwan, Bulgaria, Switzerland, Mexico
AstraZeneca
Merck Sharp & Dohme LLC; Myriad Genetic Laboratories, Inc.

Completed

Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy (POLO)

Metastatic Adenocarcinoma of the Pancreas | Germline BRCA1/2 Mutations and

United States, France, Italy, Spain, United Kingdom, Belgium, Canada, Germany, Korea, Republic of, Australia, Israel, Netherlands
AstraZeneca
Merck Sharp & Dohme LLC; Myriad Genetic Laboratories, Inc.

Completed

Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments (SOLO3)

Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity

United States, Italy, Spain, Belgium, Poland, Canada, Korea, Republic of, Brazil, Czechia, Hungary, Israel, Argentina, Mexico
Triple-Gene, LLC
Intrexon Corporation; Precigen, Inc

Completed

Novel INXN-4001 Triple Effector Plasmid in Heart Failure

Cardiovascular Diseases | Heart Failure | Heart-Assist Device

United States
Reproductive & Genetic Hospital of CITIC-Xiangya
Merck Sharp & Dohme LLC

Completed

Effectiveness of Estradiol Valerate Pretreatment in Antagonist Protocol for Poor Ovarian Response Patient

Infertility

China
Chong Qing Reproducive and Genetic Institute
Merck Sharp & Dohme LLC

Unknown

Effectiveness and Safety Study of Fixed Versus Flexible of Gonadotropin-releasing Hormone Antagonist Protocol (GnRH)

Infertility
AstraZeneca
Merck Sharp & Dohme LLC; GOG Foundation; Myriad Genetic Laboratories, Inc.

Active, not recruiting

Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. (SOLO-1)

Advanced Ovarian Cancer | Newly Diagnosed | FIGO Stage III-IV | Partial Response | Complete Response | BRCA Mutation | First Line Platinum Chemotherapy

Korea, Republic of, France, Italy, United States, Israel, Canada, China, Brazil, United Kingdom, Poland, Australia, Japan, Netherlands, Russian Federation, Spain
AstraZeneca
Merck Sharp & Dohme LLC; European Network of Gynaecological Oncological Trial... and other collaborators

Active, not recruiting

Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

Relapsed Ovarian Cancer | Following Complete or Partial Response to Platinum Based Chemotherapy | Platinum Sensitive | BRCA Mutated

Korea, Republic of, France, China, Italy, United States, Israel, United Kingdom, Canada, Japan, Germany, Brazil, Netherlands, Belgium, Poland, Australia, Russian Federation, Spain
University Hospital, Geneva
Merck Sharp & Dohme LLC; Center for Primary Care and Public Health (Unisante)...

Completed

Understanding Barriers and Facilitators to the Participation of Women Living With HIV in Clinical Trials : a Mixed-method Study (EVA) (EVA)

HIV

Switzerland
N-Gene Research Laboratories, Inc.
Thermo Fisher Scientific, Inc; Integrium; Msource Medical Development GmbH; Kinexum... and other collaborators

Terminated

Safety and Efficacy of BGP-15 in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus

United States, Germany, Hungary
AstraZeneca
Merck Sharp & Dohme LLC; NRG Oncology; Breast International Group; Myriad Genetic... and other collaborators

Active, not recruiting

Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer (OlympiA)

Breast Cancer

United States, Austria, Italy, Spain, Sweden, United Kingdom, Belgium, Poland, France, Switzerland, Canada, Germany, Korea, Republic of, Netherlands, Japan, China, Taiwan, Australia, Argentina, Israel, Hungary, Portugal, Iceland, Puerto...
University Hospital, Geneva
University of Lausanne Hospitals; University Hospital St Luc, Brussels; University... and other collaborators

Completed

Neurally Adjusted Ventilatory Assist for Non Invasive Ventilation and Patient-ventilator Interaction

Non Invasive Ventilation | Patient Ventilator Interaction

Belgium, Switzerland
Université Catholique de Louvain
Centre Hospitalier Universitaire Vaudois; Cliniques universitaires Saint-Luc-... and other collaborators

Unknown

Testing Interference-based Methods to Mitigate Gambling Craving - A Multiple Single Case Design

Craving | Gambling | Gambling Disorder | Gambling, Pathological | Gambling Problem

Switzerland
University of Michigan
Wayne State University; Henry Ford Health System; Agency for Healthcare Research... and other collaborators

Completed

Pulsed UV Xenon Disinfection to Prevent Resistant Healthcare Associated Infection

Clostridium Difficile Infection | Healthcare Associated Infection | Infection Due to Multidrug Resistant Bacteria

United States
University Hospital, Ghent
University Hospital, Antwerp; AZ Jan Palfijn Gent; Gedeon Richter Plc.; Our Lady...

Terminated

Myo-inositol Versus Clomiphene Citrate in PCOS

Polycystic Ovary Syndrome | Ovulation Induction | Clomiphene | Inositol

Belgium
Universitaire Ziekenhuizen KU Leuven
University Hospital, Ghent; Academisch Medisch Centrum - Universiteit van Amsterdam... and other collaborators

Unknown

Prospective Study Investigating the Role of Occupational Exposure on Sinus Surgery Outcome

Rhinosinusitis
University Hospital, Geneva
University Hospital, Angers; University Hospital, Clermont-Ferrand; Centre Hospitalier... and other collaborators

Completed

Age-adjusted D-dimer Cut-off to Rule Out Pulmonary Embolism in the Emergency Department : A Real Life Impact Study (RELAX-PE)

Pulmonary Embolism

Switzerland, Belgium, France
PD Dr. Grégoire Wuerzner
University Hospital, Geneva; Central Hospital, Nancy, France; Universitair Ziekenhuis... and other collaborators

Completed

Blood Pressure Measurement in Dialysed Patients (DIALBP)

End Stage Renal Disease

Switzerland
State University of New York at Buffalo
Children's Hospital of Philadelphia; University of Pennsylvania; United States... and other collaborators

Not yet recruiting

Exercise Reset for Concussion in a Military Environment

Brain Concussion
AstraZeneca
Contract Research Organization: USA; PAREXEL Early Phase Clinical Unit Baltimore and other collaborators

Completed

A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA

Asymptomatic Hyperuricemia

United States
Merck KGaA, Darmstadt, Germany
Merck Serono GmbH, Germany; Merck B.V., Netherlands; Merck A.E., Greece; Merck... and other collaborators

Completed

PERgoveriS In Stratified Treatment for Assisted Reproductive Technique (PERSIST)

Assisted Reproductive Techniques | Reproductive Technology, Assisted

Italy, Russian Federation, United Kingdom, Germany, Poland, Finland, Slovakia, Netherlands, Denmark, France, Greece
University of British Columbia
Eli Lilly and Company; Merck Sharp & Dohme LLC; Pfizer; Canadian Institutes of... and other collaborators

Recruiting

National Active Surveillance Network and Pharmacogenomics of Adverse Drug Reactions in Children

Adverse Drug Reaction (ADR)

Canada
Amoneta Diagnostics SAS
Assistance Publique - Hôpitaux de Paris; University Hospital, Geneva; University... and other collaborators

Unknown

ADDIA Proof-of-Performance Clinical Study (ADDIA)

Frontotemporal Lobar Degeneration | Progressive Supranuclear Palsy (PSP) | Dementia With Lewy Bodies (DLB) | Corticobasal Degeneration (CBD) | Alzheimer Disease (AD) | Parkinson Disease Dementia (PDD)

Belgium, France, Italy, Switzerland, Turkey

Clinical Trials Sponsored by GeneTX Biotherapeutics, LLC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cyprus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations